Deutsche Bank AG Makes New $2.49 Million Investment in CytomX Therapeutics, Inc. $CTMX

Key Points

• Deutsche Bank acquired 663,038 shares of CytomX Therapeutics valued at approximately $2.49 million, representing about 0.39% of the company. Institutional investors collectively own 67.77% of CTMX.
• CytomX reported quarterly EPS of negative $0.09, missing estimates by $0.01, while revenue of $1.42 million fell well short of the $12.39 million consensus forecast. The company continues to post substantial losses.
• CTMX recently traded at $3.42, compared with a 52-week range of $1.90 to $8.21. Despite mixed analyst opinions, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.90.

Deutsche Bank AG bought a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 663,038 shares of the biotechnology company's stock, valued at approximately $2,486,000. Deutsche Bank AG owned about 0.39% of CytomX Therapeutics as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Wells Fargo & Company MN increased its position in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company's stock worth $28,000 after buying an additional 3,000 shares during the last quarter. Invesco Ltd. bought a new position in shares of CytomX Therapeutics during the 2nd quarter worth $32,000. Goldman Sachs Group Inc. purchased a new stake in CytomX Therapeutics in the 1st quarter worth about $39,000. May Hill Capital LLC purchased a new stake in CytomX Therapeutics in the 4th quarter worth about $46,000. Finally, Lido Advisors LLC bought a new stake in CytomX Therapeutics in the 1st quarter valued at about $49,000. Hedge funds and other institutional investors own 67.77% of the company's stock.

CytomX Therapeutics Price Performance

CTMX stock opened at $3.42 on Friday. CytomX Therapeutics, Inc. has a one year low of $1.90 and a one year high of $8.21. The stock has a market cap of $745.22 million, a PE ratio of -6.84 and a beta of 2.12. The firm has a 50 day simple moving average of $3.45 and a two-hundred day simple moving average of $4.04.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The company had revenue of $1.42 million for the quarter, compared to analysts' expectations of $12.39 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. On average, research analysts expect that CytomX Therapeutics, Inc. will post -0.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CTMX. Weiss Ratings reiterated a "sell (d)" rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. JPMorgan Chase & Co. dropped their price target on shares of CytomX Therapeutics from $12.00 to $11.00 and set an "overweight" rating on the stock in a research note on Thursday, August 13th. Guggenheim reduced their price objective on shares of CytomX Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Wolfe Research initiated coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They set an "outperform" rating and a $6.00 target price on the stock. Finally, Wall Street Zen lowered CytomX Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 23rd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $11.90.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source